Walgreens, CVS emphasize personal value as Amazon threat looms

Feeling the pressure from the ever-growing presence of Amazon in the healthcare space, CVS Health and Walgreens are emphasizing their abilities to connect with patients face to face, Forbes reported.

Both brick-and-mortar companies are stressing their new partnerships with healthcare providers and services to fend off–if not explicitly–competitive threats from Amazon, which has ramped up its own initiatives in the healthcare market.

CVS is currently underway with a $69 billion acquisition of Aetna, a health insurance provider. Walgreens has forged several new partnerships, including connecting with Humana in a pilot to set up two primary care clinics for senior in Kansas. Walgreens also recently launched a digital platform and marketplace to serve customers.

Amazon, meanwhile, has acquired online pharmacy PillPack, launched its own over-the-counter medicines brand and is working on a joint venture to improve healthcare insurance costs and options for its employees with Berkshire Hathaway and JPMorgan Chase.

“But Amazon lacks a partnership with a major health insurance company, which would be a game changer if it happened or if Amazon began developing closer ties to medical care providers,” Bruce Japson for Forbes wrote.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.